Pandemic Crisis Management in the Saudi Arabian Healthcare Setting: An Evidence-Based Framework for Immunization Campaigns

The COVID-19 pandemic revealed systemic vulnerabilities in global healthcare frameworks, highlighting the critical need for regional, data-driven health policy reforms. Within the Kingdom of Saudi Arabia (KSA), the Ministry of Health (MOH) executed robust initiatives to mitigate viral transmission and lower case-fatality rates. However, sustaining healthcare resilience requires continuous refinement of clinical and preventative protocols. Therefore there is an urgent need for a policy directive to ensure better preparedness for any upcoming pandemics.  This policy paper synthesizes local epidemiological data, evaluates emerging oral and combination therapies, and analyzes socio-demographic barriers to childhood vaccination campaigns. By bridging the gap between clinical research and structural administration, this document outlines a comprehensive framework designed to optimize the Saudi healthcare response. Key strategic priorities include the codification of novel oral therapeutics (e.g., molnupiravir and quercetin) within standard clinical guidelines, the operationalization of rapid-recovery clinical pathways to mitigate economic and life expectancy losses, and the deployment of targeted, culturally specific communications to eradicate childhood vaccine hesitancy.

1. Asdaq SMB, Rabbani SI, Alshammari MK, Alshammari RS, Kamal M, Imran M, et al. Burden of COVID-19: A preliminary analysis in the population of Saudi Arabia. PeerJ. 2022;10:e13219. doi:10.7717/peerj.13219
2. Alshammari MK, Fatima W, Alraya RA, Khuzaim Alzahrani A, Kamal M, Alshammari RS, et al. Selenium and COVID-19: A spotlight on the clinical trials, inventive compositions, and patent literature. J Infect Public Health. 2022;15(11):1225-33. doi:10.1016/j.jiph.2022.09.011
3. Khan YH, Mallhi TH, Khan TM, Salman M. Advances in infectious diseases and clinical microbiology during the COVID-19 pandemic. Medicina (Kaunas). 2022;58(10):1362. doi:10.3390/medicina58101362
4. Asdaq SMB, Rabbani SI, Alkahtani M, Aldohyan MM, Alabdulsalam AM, Alshammari MS, et al. A patent review on the therapeutic application of monoclonal antibodies in COVID-19. Int J Mol Sci. 2021;22(21):11953. doi:10.3390/ijms222111953
5. Alrashed AA, Khan TM, Alhusseini NK, Asdaq SMB, Enani M, Alosaimi B, et al. Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study. J Infect Public Health. 2021;14(6):726-33. doi:10.1016/j.jiph.2021.03.004
6. Imran M, Fatima W, Alzahrani AK, Suhail N, Alshammari MK, Alghitran AA, et al. Development of therapeutic and prophylactic zinc compositions for use against COVID-19: A glimpse of the trends, inventions, and patents. Nutrients. 2022;14(6):1227. doi:10.3390/nu14061227
7. Imran M, Kumar Arora M, Asdaq SMB, Khan SA, Alaqel SI, Alshammari MK, et al. Discovery, development, and patent trends on molnupiravir: A prospective oral treatment for COVID-19. Molecules. 2021;26(19):5795. doi:10.3390/molecules26195795
8. Imran M, Thabet HK, Alaqel SI, Alzahrani AR, Abida A, Alshammari MK, et al. The therapeutic and prophylactic potential of quercetin against COVID-19: An outlook on the clinical studies, inventive compositions, and patent literature. Antioxidants (Basel). 2022;11(5):876. doi:10.3390/antiox11050876
9. Sharma SK, Bhatt P, Asdaq SMB, Alshammari MK, Alanazi A, Alrasheedi NS, et al. Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review. J Infect Public Health. 2022;15(5):566-72. doi:10.1016/j.jiph.2022.03.014
10. AlOsaimi HM, Alqahtani AM, Alanazi NM, Alotibi NN, Alrazog MS, Aljameel HA, et al. Barriers and motivators toward childhood COVID-19 vaccination: A cross-sectional study conducted among Saudi population. Medicina (Kaunas). 2023;59(12):2050. doi:10.3390/medicina59122050
11. Salman M, Mallhi TH, Tanveer N, Shehzadi N, Khan HM, Ul Mustafa Z, et al. Evaluation of conspiracy beliefs, vaccine hesitancy, and willingness to pay towards COVID-19 vaccines in six countries from Asian and African regions: A large multinational analysis. Vaccines (Basel). 2022;10(11):1866. doi:10.3390/vaccines10111866
12. Yaseen MO, Saif A, Khan TM, Yaseen M, Saif A, Bukhsh A, et al. A qualitative insight into the perceptions and COVID-19 vaccine hesitancy among Pakistani pharmacists. Hum Vaccin Immunother. 2022;18(1):2031455. doi:10.1080/21645515.2022.2031455
13. Ahmed A, Lee KS, Bukhsh A, Al-Worafi YM, Sarker MMR, Ming LC, et al. Outbreak of vaccine-preventable diseases in Muslim majority countries. J Infect Public Health. 2018;11(2):153-5. doi:10.1016/j.jiph.2017.09.007
14. Munir MZ, Khan AH, Khan TM. Healthcare professionals' understanding and perception of drug-related issues linked to off-label pharmacological medications used for COVID-19. Expert Rev Anti Infect Ther. 2024;22(6):487-93. doi:10.1080/14787210.2024.2310004